Salmeterol
Based on 8 publication(s) in Google Scholar
Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.69%
- No. CAS: 89365-50-4
- Fòrmula: C25H37NO4
- Peso molecular:415.57
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Salmeterol
More- Nat Commun. 2020 Sep 25;11(1):4857. [Abstract]
- Neuron. 2024 Jul 25:S0896-6273(24)00494-X. [Abstract]
- Mol Ther. 2025 May 8:S1525-0016(25)00382-X. [Abstract]
- J Pharm Anal. 2024 Jul;14(7):100934. [Abstract]
- Cell Rep. 2019 Dec 3;29(10):2929-2935.e4 [Abstract]
- Neurobiol Dis. 2020 Jul;140:104874. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Drug Test Anal. 2021 Feb;13(2):283-298. [Abstract]
-
Others
-
WB
Ver todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
|
β2 adrenoceptor 9.6 (pEC50) |
β1 adrenoceptor 6.1 (pEC50) |
β3 adrenoceptor 5.9 (pEC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.07 nM
Compound: Salmeterol
|
Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method
Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method
|
[PMID: 20804199] |
| CHO | EC50 |
0.07 nM
Compound: salmeterol
|
Agonist activity at human recombinant beta-2 adrenoceptor expressed in CHO cells assessed as elevation of cAMP
Agonist activity at human recombinant beta-2 adrenoceptor expressed in CHO cells assessed as elevation of cAMP
|
[PMID: 17498952] |
| CHO | EC50 |
0.07 nM
Compound: salmeterol
|
Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels
Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels
|
[PMID: 17897826] |
| HEK293 | EC50 |
0.33 nM
Compound: 2
|
Agonist activity at human beta2-adrenoceptor expressed in HEK cells assessed as increase of cAMP level after 10 mins by radioimmunoassay
Agonist activity at human beta2-adrenoceptor expressed in HEK cells assessed as increase of cAMP level after 10 mins by radioimmunoassay
|
[PMID: 21310610] |
Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human T lymphocytes (THP-1 cells)
-
Concentration:0.001, 0.01, 0.05, 0.2, 1, 5, and 25 µM
-
Incubation Time:
-
Result:The proliferation of Th2 cells was inhibited in a concentration dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g)[3]
-
Dosage:Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg)
-
Administration:The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period.
-
Result:COPD assessment test scores were markedly improved in mice with COPD.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 89365-50-4
-
Appearance Solid
-
Peso molecular 415.57
-
Fòrmula C25H37NO4
-
Color White to off-white
-
SMILES
OC1=CC=C(C(O)CNCCCCCCOCCCCC2=CC=CC=C2)C=C1CO
-
Synonyms
GR33343X
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. [Abstract]2020 Sep 25;11(1):4857. PMID: 32978402 -
Neuron
2024 Jul 25:S0896-6273(24)00494-X. PMID: 39094559 -
Mol Ther
Renal tubular epithelial IGFBP7 interacts with PKM2 to drive renal lipid accumulation and fibrosis. [Abstract]2025 May 8:S1525-0016(25)00382-X. PMID: 40346800 -
J Pharm Anal
Baicalin reduces chronic stress-induced breast cancer metastasis via directly targeting β2-adrenergic receptor. [Abstract]2024 Jul;14(7):100934. PMID: 39139999
Salmeterol purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2024 Jul;14(7):100934. [Abstract]
MDA-MB-231 and 4T1 cells were treated with BA, isoproterenol (ISO)/Salmeterol (SAL), or BA plus ISO/SAL, and the intracellular cyclic adenosine monophosphate (cAMP) level was detected.
Salmeterol purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2024 Jul;14(7):100934. [Abstract]
The protein expression levels of EMT markers (E-cadherin, N-cadherin, MMP2, and vimentin) were detected in 4T1 cells treated with BA, Salmeterol (SAL), or SAL combined with BA.
-
Cell Rep
2019 Dec 3;29(10):2929-2935.e4 PMID: 31801060 -
Neurobiol Dis
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome. [Abstract]2020 Jul;140:104874. PMID: 32325119 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Drug Test Anal
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]2021 Feb;13(2):283-298. PMID: 32852861
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (240.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Panayiotis A Procopiou, et al. The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. Bioorg Med Chem. 2011 Oct 15;19(20):6026-32. [Content Brief]
[2]. Malcolm Johnson. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S282-90. [Content Brief]
[3]. Zhiyuan Wang, et al. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp Ther Med. 2018 Feb;15(2):1538-1545. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4063 mL | 12.0317 mL | 24.0633 mL | 60.1583 mL |
| 5 mM | 0.4813 mL | 2.4063 mL | 4.8127 mL | 12.0317 mL | |
| 10 mM | 0.2406 mL | 1.2032 mL | 2.4063 mL | 6.0158 mL | |
| 15 mM | 0.1604 mL | 0.8021 mL | 1.6042 mL | 4.0106 mL | |
| 20 mM | 0.1203 mL | 0.6016 mL | 1.2032 mL | 3.0079 mL | |
| 25 mM | 0.0963 mL | 0.4813 mL | 0.9625 mL | 2.4063 mL | |
| 30 mM | 0.0802 mL | 0.4011 mL | 0.8021 mL | 2.0053 mL | |
| 40 mM | 0.0602 mL | 0.3008 mL | 0.6016 mL | 1.5040 mL | |
| 50 mM | 0.0481 mL | 0.2406 mL | 0.4813 mL | 1.2032 mL | |
| 60 mM | 0.0401 mL | 0.2005 mL | 0.4011 mL | 1.0026 mL | |
| 80 mM | 0.0301 mL | 0.1504 mL | 0.3008 mL | 0.7520 mL | |
| 100 mM | 0.0241 mL | 0.1203 mL | 0.2406 mL | 0.6016 mL |